Global X China Biotech ETF | 2820 | Global X ETFs Hong Kong
1755423724
Hong Kong (SAR)
Our Products Research
Subscribe Search

Global X China Biotech ETF

2820 HKD
9820 USD

Invest in 2820 /9820

Important Information

Investors should not base investment decisions on this material alone. Please refer to the Prospectus for details including the product features and the risk factors. Investment involves risks. Past performance is not indicative of future performance. There is no guarantee of the repayment of the principal. Investors should note:

  • The investment objective of Global X China Biotech ETF’s (the “Fund”) is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive China Biotech Index.
  • The Fund is exposed to concentration risk by tracking a single region or country.
  • The Index constituents may be concentrated in a specific industry or sector, which may potentially more volatile than a fund with a diversified portfolio.
  • Biotech companies invest heavily in research and development which may not necessarily lead to commercially successful products, and the ability for biotech companies to obtain regulatory approval (for example, product approval) may be long and costly.
  • Investment in Emerging Market, such as A-share market, may involve increased risks and special considerations not typically associated with investments in more developed markets, such as liquidity risk, currency risks, political risk, legal and taxation risks, and the likelihood of a high degree of volatility.
  • The Stock Connect is subject to quota limitations. Where a suspension in the trading through the Stock Connect is effected, the Sub-Fund’s ability to invest in A-Shares or access Mainland China markets through the programme will be adversely affected.
  • Listed companies on the ChiNext market and/or STAR Board are usually subject to higher fluctuation in stock prices and liquidity risks, over-valuation risk, differences in regulation, delisting risk, and concentration risk.
  • There are risks and uncertainties associated with the current Mainland China tax laws, regulations and practice in respect of capital gains realized via Stock Connect on the Fund’s investments in Mainland China. Any increased tax liabilities on the Fund may adversely affect the Fund’s value.
  • The trading price of the Fund’s unit on the SEHK is driven by secondary market trading factors, which may lead to a substantial premium or discount to the Fund’s net asset value.
  • The Fund’s synthetic replication strategy may invest up to 50% of its net asset value in financial derivative instruments (“FDIs”), which may expose the Fund to counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. The Fund may suffer losses from its usage of FDIs.
  • The Manager may at its discretion pay dividends out of the capital of the Fund. Distributions paid out of capital, represent a return of an investor’s original investment or its gains and may potentially reduce the Fund’s Net Asset Value per Share as well as the capital available for future investment.
  • The Fund may suffer from a losses or delays when recovering the securities lent out. This may potentially affect its ability to meet payment and redemption obligations. Collateral shortfalls due to inaccurate pricing or change of value of securities lent, may cause significant losses to the Fund.

Why Global X China Biotech ETF? Product Flyer 

  • We see upside potential for China Biotech Sector as bolstered by domestic policy support and Chinese companies’ overseas expansion. China’s macro easing policy and US FOMC rate cuts bode well for better funding environment for biotech companies to support R&D activity.
  • Biotech sector valuation is nearing 5 year trough. Profitability improvement and commercialization ramp-up for biotech companies could lead to improving investor sentiments towards China healthcare.
  • AI application in biotech sectors could further accelerate with the emergence of cost-efficient models, which could bring further efficiency gains and cost savings for biotech companies.

Fund InformationAs of 14 Aug 2025

Fund Inception Date 24 Jul 2019
SEHK Listing Date 25 Jul 2019
Fiscal Year Ending 31 Mar
Ongoing Charges Over A Year ^ 0.68%
Distribution Frequency Annually at the Manager's discretion (May in each year).
NAV Per Share RMB $69.20
Monthly Report
^ The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. Click to learn more.

Index Information1As of 14 Aug 2025

Underlying Index Solactive China Biotech Index NTR 2
Index Type Net Total Return
Base Currency RMB
Closing Level 2,082.84
Change 8.61
Change % 0.42%

Trading InformationAs of 14 Aug 2025

HKD Traded Units3 USD Traded Units3
Exchange Hong Kong Stock Exchange
Stock Code 2820
ISIN HK0000516697
Board Lot Size 50 Units
Trading Currency HKD
Base Currency RMB
Total Net Asset Value $551,152,964.70
Outstanding Units 7,300,000

ETF Summary

The Global X China Biotech ETF (2820/9820) seeks to invest in companies involved in the development of biotechnology in China, including companies whose principal business is in research, development, manufacturing, and distribution of new drugs, therapies, or vaccines using biological materials.

The Fund is a passive ETF and seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Solactive China Biotech Index NTR (the “Index”).

Research

View More Related Research

ETF Prices

* Market prices are provided on a 15-minute delayed basis by ICE Data Services. (See terms and conditions)

Daily NAV per Unit5As of 14 Aug 2025

NAV Change % Change
Official NAV per Unit in RMB $69.20 $0.29 0.42%
NAV per Unit in HKD 3 $75.50 $0.31 0.42%
NAV per Unit in USD3 $9.64 $0.04 0.42%

Performance As of 14 Aug 2025

Cumulative Return Fund NAV (%) Benchmark (%)
1 Mth 14.99 15.19
3 Mths 41.09 41.60
6 Mths 53.63 54.39
1 Yr 77.37 78.90
YTD 61.83 62.85
Since Inception 38.41 45.90
Calendar Year Return Fund NAV (%) Benchmark (%)
2024 -17.46 -16.91
2023 -12.92 -12.32
2022 -26.09 -25.52
2021 -19.65 -19.17
2020 69.70 71.88
Source: Mirae Asset Global Investments (Hong Kong) Limited.
• Past performance information is not indicative of future performance. Investors may not get back the full amount invested.
• The computation basis of the performance is based on the calendar year end, Net Asset Value to Net Asset Value.
• These figures show by how much the Fund increased or decreased in value during the calendar year shown. Performance data has been calculated in RMB including ongoing charges and excluding trading costs on SEHK you might have to pay.
• Where no past performance is shown, there was insufficient data available in that year to provide performance.
• The Index of the Fund is Solactive China Biotech Index.
• Fund inception date: 24 July 2019

Exposure As of 31 Jul 2025

    Weight (%)
Health Care 99.8
Cash 0.2
    Weight (%)
China 99.8
Cash 0.2

Holdings Overview As of 14 Aug 2025

Total Net Asset Value (in HKD) Total Net Asset Value (in USD) Total Net Asset Value (in RMB) Number of Securities Securities (%) Cash and Cash Equivalent (%)
551,152,964.70 70,369,334.52 505,181,452.52 30 99.79 0.21

Daily HoldingsAs of 14 Aug 2025

Name of Securities Exchange Ticker Exchange Market Price (in RMB) Number of Shares Held Market Value (in RMB) Net Assets (%)
WUXI APPTEC 603259 C1 Shanghai 98.68 501,302 49,468,481.36 9.79
BEONE MEDICINES-ADR ONC US New York 2,223.25 21,558 47,928,849.50 9.49
INNOVENT BIOLOGICS INC 1801 HK Hong Kong 87.99 525,308 46,221,311.49 9.15
WUXI BIOLOGICS CAYMAN INC 2269 HK Hong Kong 28.25 1,585,345 44,783,026.23 8.86
JIANGSU HENGRUI PHARMACEUT 600276 C1 Shanghai 62.82 680,188 42,729,410.16 8.46
AKESO INC 9926 HK Hong Kong 150.50 250,766 37,739,732.85 7.47
SINO BIOPHARMACEUTICAL 1177 HK Hong Kong 6.98 4,104,531 28,666,556.51 5.67
3SBIO INC 1530 HK Hong Kong 29.29 749,895 21,966,670.96 4.35
HANSOH PHARMACEUTICAL GROUP 3692 HK Hong Kong 34.44 490,642 16,899,681.28 3.35
SHANGHAI RAAS BLOOD PRODUC 002252 C2 Shenzhen 6.90 2,092,800 14,440,320.00 2.86
ZAI LAB-ADR ZLAB US New York 250.76 55,187 13,838,745.62 2.74
PHARMARON BEIJING 300759 C2 Shenzhen 30.17 342,900 10,345,293.00 2.04
HEBEI CHANGSHAN BIOCHEMICA 300255 C2 Shenzhen 48.18 205,000 9,876,900.00 1.96
REMEGEN 688331 C1 Shanghai 73.78 123,852 9,137,800.56 1.81
HANGZHOU TIGERMED CONSULTI 300347 C2 Shenzhen 68.91 132,200 9,109,902.00 1.81
SICHUAN BIOKIN PHARMACEUTI 688506 C1 Shanghai 314.70 27,960 8,799,012.00 1.74
MGI TECH 688114 C1 Shanghai 67.81 124,759 8,459,907.79 1.67
BEIJING TIANTAN BIOLOGICAL 600161 C1 Shanghai 20.12 407,200 8,192,864.00 1.62
GENSCRIPT BIOTECH CORP 1548 HK Hong Kong 16.04 509,375 8,170,200.06 1.62
GAN & LEE PHARMACEUTICALS 603087 C1 Shanghai 62.04 131,200 8,139,648.00 1.62
SHANGHAI ALLIST PHARMACEUT 688578 C1 Shanghai 90.01 84,832 7,635,728.32 1.51
SHANGHAI JUNSHI BIOSCIENCE 688180 C1 Shanghai 42.72 161,774 6,910,985.28 1.36
HUALAN BIOLOGICAL ENGINEER 002007 C2 Shenzhen 16.71 412,800 6,897,888.00 1.36
CHINA MEDICAL SYSTEM HOLDING 867 HK Hong Kong 11.97 555,783 6,652,815.08 1.32
LIVZON PHARMACEUTICAL GROU 000513 C2 Shenzhen 39.65 159,500 6,324,175.00 1.25
XIAMEN AMOYTOP BIOTECH 688278 C1 Shanghai 85.50 73,009 6,242,269.50 1.24
SICHUAN KELUN-BIOTECH BIOP 6990 HK Hong Kong 397.42 15,349 6,099,951.41 1.21
BEIJING WANTAI BIOLOGICAL 603392 C1 Shanghai 54.51 110,800 6,039,708.00 1.19
HUBEI JUMPCAN PHARMACEUT 600566 C1 Shanghai 26.59 168,300 4,475,097.00 0.89
SUNSHINE GUOJIAN PHARMACEU 688336 C1 Shanghai 51.44 37,008 1,903,691.52 0.38
Source: Mirae Asset, Bloomberg
Holdings are subject to change. Cash, where shown, includes other assets and liabilities, such as payables and receivables.
20250814.41590.415093793841582082.84

Tracking Difference / Error

Tracking Difference / Tracking Error

Tracking Difference
Tracking difference is the return difference between the Fund and the Underlying Index over a certain period of time.
Tracking Error
Tracking error measures how consistently the Fund follows the Underlying Index. It is the volatility (measured by standard deviation) of that return difference.

Tracking Difference (TD)

Fund Listing Date:25 Jul 2019

Rolling 1 Year TD: N/A

TD for Calendar Year 2024:-0.55%

TD for Calendar Year 2023:-0.60%

TD for Calendar Year 2022:-0.57%

TD for Calendar Year 2021:-0.48%

TD for Calendar Year 2020:-2.18%

Tracking Error (TE)

Fund Listing Date:25 Jul 2019

Rolling 1 Year TE^ :N/A%

^ Annualized based on the number of dealing days in the past year when daily TD is calculated.


Graph for Tracking Difference

ETFs performance is calculated on an NAV to NAV basis and assumes reinvestment of distribution.

Hover over the chart points for details

Market Makers 6

Flow Traders Hong Kong Limited

Mirae Asset Securities Co., Ltd.

Participating Dealers 7

ABN AMRO Clearing Hong Kong Limited

Barclays Bank PLC

China Galaxy International Securities (Hong Kong) Co., Limited

China Merchants Securities (HK) Co., Limited

Citigroup Global Markets Asia Limited

DBS Vickers (Hong Kong) Limited

Haitong International Securities Company Limited

Merrill Lynch Far East Limited

Mirae Asset Securities (HK) Limited

SinoPac Securities (Asia) Limited

Yuanta Securities (Hong Kong) Company Limited

Product Documents

Monthly Returns

Announcements / Notices

Back to Top

You’re now leaving Global X Hong Kong website


Clicking "Confirm" below will take you to an independent site. Information and services provided on this independent site are not reviewed by, guaranteed by, or Global X Hong Kong. This independent site's terms and conditions, privacy and security policies, or other legal information may be different from those of Global X Hong Kong’s site. Global X Hong Kong is not liable for any direct or indirect technical or system issues, consequences, or damages arising from your use of this independent website.



CancelConfirm

This website is intended for Hong Kong investors only. Your use of this website means you agree to our Terms of use. This website is strictly for informational purposes only and does not constitute a representation that any investment strategy is suitable or appropriate for an investor’s individual circumstances. In 2018, Global X was acquired by Mirae Asset Global Investments and Mirae Asset Global Investments Co., Ltd. is the parent company of Mirae Asset Global Investments (Hong Kong) Limited.

The information contained in this website is for information purposes only and does not, constitute any recommendations, offer or solicitation to buy, sell or subscribe to any securities or financial instruments in any jurisdiction. Investment involves risk. It cannot be guaranteed that the performance of the Product will generate a return and there may be circumstances where no return is generated or the amount invested is lost. Past performance is not indicative of future performance.

Before making any investment decision to invest in the Product, investors should read the Product’s prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Product and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investments.

Certain information contained in this website is compiled from third party sources. Whilst Mirae Asset Global Investments (Hong Kong) Limited (“Mirae Asset HK”), the Manager of the Product, has, to the best of its endeavor, ensured that such, information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information. Mirae Asset HK accepts no liability for, any loss or damage of any kind resulting out of the unauthorized use of this website.

The Products are not sponsored, endorsed, issued, sold or promoted by their index providers. For details of an index provider including any disclaimer, please refer to the relevant Product’s offering documents.

The contents of this website is prepared and maintained by Mirae Asset Global Investments (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.